FDA - Adverse Event Reporting System (FAERS)

Similar documents
FDA Adverse Event Reporting System (FAERS) FOIA Case Report Information

CITIZENS PETITION TO FOOD AND DRUG ADMINISTRATION. Division of Dockets Management Food and Drug Administration Room Fishers Lane

SUSPECT ADVERSE REACTION REPORT

SUSPECT ADVERSE REACTION REPORT

SUSPECT ADVERSE REACTION REPORT

FDA Adverse Event Reporting System (FAERS) FOIA Case Report Information

SUSPECT ADVERSE REACTION REPORT

SUSPECT ADVERSE REACTION REPORT

SUSPECT ADVERSE REACTION REPORT

SUSPECT ADVERSE REACTION REPORT

SUSPECT ADVERSE REACTION REPORT

SUSPECT ADVERSE REACTION REPORT

SUSPECT ADVERSE REACTION REPORT

SUSPECT ADVERSE REACTION REPORT

SUSPECT ADVERSE REACTION REPORT

Children-Adolescents: 15 suicides reported to FDA (Strattera reported as Primary Suspect Drug)

þ INVOLVED OR PROLONGED INPATIENT HOSPITALISATION

SUSPECT ADVERSE REACTION REPORT

SUSPECT ADVERSE REACTION REPORT

SUSPECT ADVERSE REACTION REPORT

SUSPECT ADVERSE REACTION REPORT

SUSPECT ADVERSE REACTION REPORT

SUSPECT ADVERSE REACTION REPORT

SUSPECT ADVERSE REACTION REPORT

SUSPECT ADVERSE REACTION REPORT

SUSPECT ADVERSE REACTION REPORT

SUSPECT ADVERSE REACTION REPORT

SUSPECT ADVERSE REACTION REPORT

BJA Performance Measures

COMMONLY PRESCRIBED PSYCHOTROPIC MEDICATIONS NAME Generic (Trade) DOSAGE KEY CLINICAL INFORMATION Antidepressant Medications*

South Plains Emergency Medical Services, Inc. P.O. Box Lubbock, Texas 79453

SUSPECT ADVERSE REACTION REPORT

SUSPECT ADVERSE REACTION REPORT

SUSPECT ADVERSE REACTION REPORT

SUSPECT ADVERSE REACTION REPORT

SUSPECT ADVERSE REACTION REPORT

SUSPECT ADVERSE REACTION REPORT

ADULTS WITH COMPLEX BEHAVIORAL SUPPORT NEEDS. Betsey Benson, Ph.D. Vanessa Rodriguez, Ph.D., BCBA-D Nisonger Institute 2015

This document was created on 07 January 2005 and has been printed from

þ INVOLVED OR PROLONGED INPATIENT HOSPITALISATION

SUSPECT ADVERSE REACTION REPORT

SUSPECT ADVERSE REACTION REPORT

SUSPECT ADVERSE REACTION REPORT

Quick Guide to Common Antidepressants-Adults

SUSPECT ADVERSE REACTION REPORT

SUSPECT ADVERSE REACTION REPORT

SUSPECT ADVERSE REACTION REPORT

SUSPECT ADVERSE REACTION REPORT

SUSPECT ADVERSE REACTION REPORT

Opioid Deaths in South Carolina. Daniela Nitcheva, PhD Division of Biostatistics Bureau of Public Health Statistics

SUSPECT ADVERSE REACTION REPORT

Consultant-led Referral to Treatment (RTT) waiting times collection timetable: outcome of consultation

SUSPECT ADVERSE REACTION REPORT

SUSPECT ADVERSE REACTION REPORT

SUSPECT ADVERSE REACTION REPORT

SUSPECT ADVERSE REACTION REPORT

Annex I. Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s)

SUSPECT ADVERSE REACTION REPORT

SUSPECT ADVERSE REACTION REPORT

AccuVert HIV-1 Seroconversion Panel PRB955 ( ) / Batch #

þ INVOLVED OR PROLONGED INPATIENT HOSPITALISATION

AccuSet HCV Performance Panel

DOWNLOAD OR READ : VASCULITIS SICK AND TIRED OF BEING SICK AND TIRED PDF EBOOK EPUB MOBI

Mar 6, The most effective medications are described in the next section. Selective serotonin reuptake inhibitors (SSRIs) SSRIs are a highly

INFLUENZA IN MANITOBA 2010/2011 SEASON. Cases reported up to January 29, 2011

Reviews/Evaluations. Use of Selective Serotonin Reuptake Inhibitors in Pediatric Patients. Pharmacotherapeutic Options

SUSPECT ADVERSE REACTION REPORT

SUSPECT ADVERSE REACTION REPORT

HIV-1 AccuVert Seroconversion Panel (PRB966) / Batch #

INFLUENZA IN MANITOBA 2010/2011 SEASON. Cases reported up to October 9, 2010

Texas Vendor Drug Program Specialty Drug List Process. February 2019

SUSPECT ADVERSE REACTION REPORT

SUSPECT ADVERSE REACTION REPORT

OFFICE OF PHARMACEUTICAL SCIENCES. COVER FORM FOR THE TECHNICAL REVIEW OF DRUG MASTER FILES (DMFs) CONTENTS

Taking Care: Child and Youth Mental Health TREATMENT OPTIONS

HDSA Annual Convention June 2013 Behavior Issues: Irritability and Depression Peg Nopoulos, M.D.

Overview of the Radiation Exposure Doses of the Workers at Fukushima Daiichi Nuclear Power Station

Article 120 Slides OTJAG, Criminal Law Policy

SUSPECT ADVERSE REACTION REPORT

McLean ebasis plus TM

Celexa and sleeping pills

Nortriptyline vs amitriptyline in elderly

Serious Adverse Event (SAE) Form Clinical Trials

Medication errors. Impact of medication error guidance and regulation on drug-device combination products. June 2017 Dan Wozinski

Antidepressant Selection in Primary Care

Published by the Pharmaceutical Services Division to provide information for British Columbia s health care providers

SUSPECT ADVERSE REACTION REPORT

Some newer, investigational approaches to treating refractory major depression are being used.

Kansas EMS Naloxone (Narcan) Administration

SUSPECT ADVERSE REACTION REPORT

APPENDIX IV: Narratives: Definitive Suicidal Behavior Events: MDD

To view past issues, go to: The New 13-Valent Pneumococcal Conjugate Vaccine (PCV13)

AccuSet Autoimmune Performance Panel

Status Date: 01-JAN APR-11 All comb. w/and

Successful Falls Prevention in Aged Persons Mental Health. Reducing the risk and decreasing severity of outcome

Magellan s Transport Route Lead Monitoring Program

Mental Health Nursing: Mood Disorders. By Mary B. Knutson, RN, MS, FCP

Average dose zoloft for ocd and anxiety

Serious Adverse Event (SAE) Form Clinical Trials

SUSPECT ADVERSE REACTION REPORT

Transcription:

Case Information: Case Type: EXPEDITED (5- DAY) esub: Y HP: Country: USA Outcomes: DE, (A)NDA/BLA: 08936 / FDA Rcvd Date: 09-Oct-204 Mfr Rcvd Date: 08-Oct-204 Mfr Control : GB-ELI_LILLY_AND_COMPANY-US890360A Patient Information: Age: 47 YR Sex: Male Weight: Suspect Products: Product Name Dose/ Frequency Route Dosage Text Indications(s) Start Date End Date PROZAC 20 MG/ Oral 20 mg, unknown Depression 0-Aug-989 -Sep-989 Interval st Product Name Dose to Event DeC ReC Lot Exp Date NDC MFR/Labeler PROZAC 36 Day A ELI LILLY AND CO Event Information: Preferred Term ( MedDRA Â Version: Aggression Agitation Fatigue Homicide Insomnia Suicide attempt Tangentiality 7.0 ) ReC Print Time: 25-AUG-205 0:05 AM If a field is blank, there is no data for that field Page 245 of 533

Event/Problem Narrative: PATIENT ENTERED HIS AND SHOT BEFORE SHOOTING HIMSELF. PRIOR TO THE SHOOTINGS, THE PATIENT HAD BEEN SEEN BY HIS PSYCHIATRIST AND EXHIBITED "TANGENTIAL THOUGHTS" AND "INCREASED LEVEL OF AGITATION AND ANGER." PATIENT * *CONT FROM SEC 7* PZ REPORTEDLY WAS D/C 3 DAYS PRIOR TO SHOOTING.PT PREVIOUSLY TAKEN PZ IN 988 BUT STOPPED TX DUE TO FATIGUE. COPY OF 02089 AND02689 NEWSPAPER ARTICLES ATTACHED. CORONER(DR. )PROVIDED ADDT'L INFO IN PHONE CONVERSATION 03089. NEWSPAPER ARTICLE MENTIONED POSSIBLE PZ ASS'N. 030 CONVERSATION W CORONER PROVIDED REPORTED BLOOD LEVELS. F/U 689: COPY OF HOSP SUMMARY FROM THE CORONER'S ATTACHED. IF FURTHER INFO RETOX OR AUTOPSY DATA BECOMES AVAILABLE, WE WILL FORWARD. **CONT'D FROM SEC. 23** 2 PREVIOUS HOSPITALIZATIONS THAT HE MIGHT LIKE TO PREVIOUS DX,IN ADDT'N TO MANIC DEPRESSIVE, INC BORDERLINE PERSONALITY W PARANOID FEATURES, DYSTHYMIC DISORDER W PARANOID TYPE PERSONALITY. F/U 2589: AUTOPSY REPORT ATTACHED. F/U /9/90: PER DR., CORONER:PT'S TIME OF DEATH LISTED @ APPROX. 8:40AM, HIS AUTOPSY STARTED AT 5:0 PM. BLOOD LEVELS DRAWN @ 5:20 PM.SITE FROM WHICHSAMPLE WAS COLLECTED WAS FROM THE HEART. F/U 7/26/90: MORE THAN A YEAR BEFORE THIS ASSAULT, PT HAD BROUGHT THIS REPORT WAS FOUND TO HAVE A DUPLICATE, US940644A, WHICH WILL BE DELETED. F/U 23NOV94: PATIENT EXPERIENCED INSOMNIA WHILE ON PROZAC. THIS IS FOUR OF FOUR CASES ALSO DESCRIBED IN THE ARTICLE: HAND J, TOBIN D. PROZAC DEFENSE MAY DEBUT IN CNY. THE POST-STANDARD. SUNDAY, NOVEMBER 7, 2002. SEE US_02089209, US_0057233 AND US950864A. THIS CASE WAS ALSO DESCRIBED IN THE FOLLOWING ARTICLE: LENZER J. FDA TO REVIEW "MISSING" DRUG COMPANY DOCUMENTS. BRITISH MEDICAL JOURNAL. 0JAN2005. THE FOLLOWING ARTICLES REPORTED ON THE ABOVE BMJ PUBLICATION THAT DESCRIBED THIS CASE:. Print Time: 25-AUG-205 0:05 AM If a field is blank, there is no data for that field Page 246 of 533

EDIT 04-DEC-2002: ADDITIONAL INFORMATION RECEIVED IN THE LITERATURE (NEWSPAPER) ON 25- NOV-2002. ADDED NON HEALTH CARE PROVIDER REPORTER AND LOCAL ID OF "LIT." ADDED LITERATURE CITATION TO NARRATIVE PAGE. ON SUSPECT DRUG PAGE ENTERED DRUG TYPE AND ANSWERED EXPOSURE CONDITIONS OF HEPATIC AND RENAL IMPAIRED. EDIT 0JAN05: UPDATED NARRATIVE PAGE TO ADD EIGHT LITERATURE CITATIONS. UPDATE 30-NOV-2006: IT WAS NOTED ON 2-NOV-2006, IN THE ARTICLE, BY HEALY, D, HERXHEIMER, A, MENKES, D, THAT THIS CASE WAS DISCUSSED. NO NEW MEDICALLY SIGNIFICANT INFORMATION WAS PROVIDED. THE SOURCE OF THE CASE WAS CHANGED FROM SPONTANEOUS TO LITERATURE. LITERATURE CITATION WAS ADDED. SEE ALSO, CASES DISCUSSED IN THE ARTICLE; GB2006000347 AND US962359A. THIS CASE WAS DESCRIBED IN THE ARTICLES: HEALY, D, HERXHEIMER, A, MENKES, D. ANTIDEPRESSANTS AND VIOLENCE: PROBLEMS AT THE INTERFACE OF MEDICINE AND LAW. PLOS MEDICINE. 2006;3(9), 478-487, AND HEALY, D, HERXHEIMER, A, MENKES, D. ANTIDEPRESSANTS AND VIOLENCE: PROBLEMS AT THE INTERFACE OF MEDICINE AND LAW. INTERNATIONAL JOURNAL OF RISK AND SAFETY IN MEDICINE. 2007; 9: 7-33. Rokuro Hama. Harmful effects of medicines; Harmful effects of selective serotonin reuptake inhibitor (SSRI). Check up your medicine. 5. 20-28. Not Reported. Medication- Induced violence towards others. Prescrire International. 23 (50) (pp 53-55), 204. Not Reported. IRS antidepressants and violence. Rev Prescrire, 2008; 28(296):43-43. UPDATE 05-DEC-2006: UPON REVIEW OF CASE NOTED THAT LISTEDNESS WAS SHOWING AS "UNKNOWN" FOR MOST OF THE EVENTS AND THERE WAS NO PSUR COMMENT. LISTEDNESS ADDED FOR EVENTS AND PSUR COMMENT ADDED. UPDATE 25JAN2008: DUPLICATE ARTICLE BY THE SAME AUTHORS IN A DIFFERENT JOURNAL RECEIVED ON 22JAN2008. ADDED REPORTER AND CITATION INFORMATION. UPDATED NARRATIVE. Update 23Jan204: A new citation was received on 2Jan204. Added citation to narrative and added author; no new clinical information was added to the case. Print Time: 25-AUG-205 0:05 AM If a field is blank, there is no data for that field Page 247 of 533

Edit 30JAN204: Edit performed to amend E2B Company number to reflect country of case. No other changes. Edit 3Jan204: Upon internal review, for submission purposes added suspect drug action taken, added the as reported descriptions for the coded events of agitation and insomnia. Edit 03Feb204: Upon internal review, removed onset date for event of fatigue as med sig edit. Update 6Sep204. A new citation was received on 5Sep204; no new clinical information was added Update 08Oct204: Additional citation received on 08Oct204 via a literature search from another article; no new clinical information added. Relevant Medical History: Disease/Surgical Procedure Start Date End Date Continuing? Medical History Product(s) Start Date End Date Indications Events Relevant Laboratory Data: Test Name Result Unit Normal Low Range Normal High Range Info Avail Concomitant Products: 2 3 Product Name LITHIUM TEMAZEPAM TRAZODONE Dose/ Frequency Route Dosage Text Indications(s) Start Date End Date Interval st Dose to Event TID UNK, 3/D UNK, unknown UNK, other Print Time: 25-AUG-205 0:05 AM If a field is blank, there is no data for that field Page 248 of 533

Reporter Source: Study Report?: No Sender Organization: ELI LILLY AND CO Literature Text: Healy, D, Herxheimer, A, Menkes, D..Antidepressants and Violence: Problems at the Interface of Medicine and Law..PLoS Medicine. 2006;3(9):478-487. Print Time: 25-AUG-205 0:05 AM If a field is blank, there is no data for that field Page 249 of 533